Abstract
Indium-111-labeled monoclonal antibody directed against prostate-specific antigen was injected into ten patients with known prostatic carcinoma, nine with metastatic disease. The monoclonal antibody scan was compared to the standard technetium bone scan, and both were correlated to clinical status and to 2-year follow-up. The ratio of target-to-nontarget activity and pharmacokinetics of the radiolabeled antibody approach may be used for staging and may be developed as a therapeutic adjuvant.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 209-220 |
| Number of pages | 12 |
| Journal | Prostate |
| Volume | 14 |
| Issue number | 3 |
| State | Published - 1989 |
ASJC Scopus subject areas
- Urology
Fingerprint Dive into the research topics of 'Development of monoclonal antibody imaging of metastatic prostatic carcinoma'. Together they form a unique fingerprint.
Cite this
Meyers, F. J., Denardo, S. J., Macey, D., deVere White, R. W., & Unger, M. (1989). Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Prostate, 14(3), 209-220.